With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

Swiss banking giant UBS said Wednesday that its net profit doubled in the second quarter thanks to a surge in transactions during global market volatility.Despite the ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...